Online inquiry

IVTScrip™ mRNA-Anti-MS4A1, SCT-400(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14686MR)

This product GTTS-WQ14686MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets MS4A1 gene. The antibody can be applied in B cell lymphoma research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001048028.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 485430
UniProt ID Q3C2E2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MS4A1, SCT-400(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ14686MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2449MR IVTScrip™ mRNA-Anti-TSLP, AMG 157(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG 157
GTTS-WQ3698MR IVTScrip™ mRNA-Anti-MSLN, BAY 2287409(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BAY 2287409
GTTS-WQ2873MR IVTScrip™ mRNA-Anti-CCR4, AMG-761(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG-761
GTTS-WQ3943MR IVTScrip™ mRNA-Anti-CTLA4, BCD-145(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BCD-145
GTTS-WQ10167MR IVTScrip™ mRNA-Anti-SELP, LC1004-002(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LC1004-002
GTTS-WQ5831MR IVTScrip™ mRNA-Anti-CD3E, ChAglyCD(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ChAglyCD
GTTS-WQ14995MR IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SJ25C1 scFv-28Z CAR
GTTS-WQ2043MR IVTScrip™ mRNA-Anti-CD274, AHLX-20(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AHLX-20
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW